MalarVx is committed to the development of a safe, effective and affordable malaria vaccine.  As a small and nimble company, our laser-focus on this single goal using novel approaches has allowed us to quickly incorporate cutting edge technologies including mRNA with nanoparticles (successfully used in COVID-19 vaccines), as well as genetically attenuated whole parasites as vaccines to completely block the transmission of malaria in animal models. 

We believe this integrated approach when tested in humans, will be instrumental in the long-term effort to eradicate both falciparum and vivax malaria in the world.